TO THE EDITOR
Tobin et al 1 has described a subset of patients with chronic lymphocytic leukaemia (CLL) using the VH3-21 gene. The majority of these cases also utilise the JH6 and Vl2-14 gene segments, have 95-98% homology to germline IgVH gene sequence and have a poor prognosis irrespective of their mutational status.
2 The same and other groups have noted biased usage of VH3-21 in association with JH6 3,4 and with VH-19 4 in mantle cell lymphoma. These cases have X98% homology to the germline sequence and prolonged survival. A feature that appears unique to VH3-21 use in CLL is that these cases that utilise JH6 almost invariably have a short CDR3 and lack a D gene segment.
We have exploited this trait to develop a Genescan technique using a framework 3 consensus primer (5 0 ACACGGC YSTGTATTACT) and a fluorescently labelled JH consensus primer (5 0 TGAGGAGACGGTCACC) to amplify the CDR3 region from the genomic DNA of CLL patients. Standard PCR conditions were used in a 12.5 ml reaction with an annealing temperature of 581C for 23 cycles. PCR product (3 ml) were added to 1 ml TAMRA 500 size standard and 12 ml of High Dye Formamide (ABI Biosystems), and then run on an ABI Genetic Analyser. Peak sizes were analysed using the Genescan software.
In all, 10 known VH3-21-positive CLLs (confirmed by sequencing) and 100 unknowns were analysed. In total, 16 possible VH3-21 cases were identified, all with short CDR3s (72-78 bps). Of these, 11 produced Genescan peaks of the same size as positive controls (75 or 76 bp). VH3-21 gene usage was confirmed by sequencing in these cases with a specific peak size of 75-76 bp. This technique would also have detected the VH3-21 cases identified by Tobin et al that lack a D segment.
In our previous study of predominantly stage A patients, only 3/205 cases expressed the VH3-21 gene.
5 The current study is confined to patients with progressive stage A, B and C cases, and the incidence of 10% usage of this gene is comparable to that reported by Tobin et al, confirming that this gene is overrepresented in patients with progressive or advanced disease.
We recognise that this rapid screening technique will only identify VH3-21 cases lacking a D segment. However, it is these cases that are of particular biological interest since they have identical or similar CDR3s (Figure 1) , suggesting the role of a common antigen in the pathogenesis of these cases. A larger study will be required to determine whether there are clinical differences between cases that either retain or lack a D segment. 
